KR920700200A - 19-노르-비타민 d 화합물 - Google Patents

19-노르-비타민 d 화합물

Info

Publication number
KR920700200A
KR920700200A KR1019900702408A KR900702408A KR920700200A KR 920700200 A KR920700200 A KR 920700200A KR 1019900702408 A KR1019900702408 A KR 1019900702408A KR 900702408 A KR900702408 A KR 900702408A KR 920700200 A KR920700200 A KR 920700200A
Authority
KR
South Korea
Prior art keywords
compound
group
hydroxy
vitamin
acyl
Prior art date
Application number
KR1019900702408A
Other languages
English (en)
Other versions
KR950013636B1 (ko
Inventor
헥터 에프. 델루카
하인리히 케이. 쉬노에스
카토 엔. 펄만
라팔 알. 시신스키
진 마틴. 프랄
Original Assignee
원본미기재
위스콘신 알럼나이 리써취 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23248877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920700200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 위스콘신 알럼나이 리써취 파운데이션 filed Critical 원본미기재
Publication of KR920700200A publication Critical patent/KR920700200A/ko
Application granted granted Critical
Publication of KR950013636B1 publication Critical patent/KR950013636B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

내용 없음

Description

19－노르－비타민 D 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (35)

  1. 하기 일반식의 화합물
    식 중, X1및 X2는 각각 수소원자, 아실, 알킬실릴 및 알콕시알킬기로 이루어진 군 중에서 선택되고, R은 알킬, 수소원자, 히드록시알킬, 플루오로알킬기 및 하기식의 측쇄로 이루어진 군 중에서 선택되며,
    여기서, R1은 수소원자, 히드록시 또는 0－아실기를 의미하고, R2및 R3는 각각 알킬, 히드록시알킬 및 플루오로알킬기로 이루어진 군 중에서 선택되거나 또는R2와 R3가 함께 －(CH2)m－(여기서, m은 2 내지 5 사이의 정수임)을 나타내고, R4는 수소원자, 히드록시, 불소원자, 0－아실, 알킬, 히드록시알킬 및 플루오로알킬기로 이루어진 군 중에서 선택되고, R5는 수소원자, 불소원자, 알킬, 히드록시알킬 및 플루오로알킬기로 이루어진 군 중에서 선택되거나 또는 R4와 R5가 함께 이중 결합으로 결합된 산소원자를 나타내고, R6와 R7은 각각 수소원자, 히드록시, 0－아실, 불소원자 및 알킬기로 이루어진 군 중에서 선택되거나, 또는 R6와 R7이 함께 탄소－탄소 이중결합을 나타내며, n은 1 내지 5 사이의 정수이고, 측쇄의 제 20, 22 또는 23 위치 중 어느 한 위치에 있는 탄소 원자는 O, S 또는 N원자에 의해 치환될 수도 있다.
  2. 제1항에 있어서, X1및 X2가 수소원자이고, R1이 히드록시기이며, R2및 R3가 모두 메틸, 트리플루오로메틸, 에틸 및 프로필기로 이루어진 군 중에서 선택되고, R6및 R7이 모두 수소원자이거나, 또는 이들이 함께 탄소－탄소 이중결합을 나타내고, R4및 R5가 수소원자이고, n이 1, 2 또는 3인 화합물.
  3. 1α, 25－디히드록시－19－노르－비타민D3
  4. 1α－히드록시－19－노르－비타민D3
  5. 1α, 25－디히드록시－19－노르－비타민D2
  6. 1α－히드록시－19－노르－비타민D2
  7. 1α－히드록시－19－노르－24－에피－비타민D3
  8. 1α, 25－디히드록시－19－노르－24－에피－비타민D2
  9. 하기 일반식의 화합물.
    식 중, R은 제1항에서 정의한 측쇄를 나타내고, Q는 알킬기이고, X는 수소원자, 아실, 알킬실릴 및 알콕시 알킬기로 이루어진 군 중에서 선택된다.
  10. 하기 일반식의 화합물.
    식 중, R은 제1항에서 정의한 측쇄를 나타내고, Q는 알킬기이고, X는 수소원자, 아실, 알킬실릴 및 알콕시 알킬기로 이루어진 군 중에서 선택된다.
  11. 하기 일반식의 화합물.
    식 중, R은 제1항에서 정의한 측쇄를 의미하고, Q는 알킬기이고, X는 수소원자, 아실, 알킬실릴 및 알콕시 알킬기로 이루어진 군 중에서 선택되고, Y는 히드록시, 수소원자 및 보호된 히드록시기(여기서, 보호기는 아실, 알킬실릴 또는 알콕시알킬임)로 이루어진 군 중에서 선택된다.
  12. 제1항의 화합물 1종 이상의 악성 종양 세포의 분화를 유발하기에 충분한 양으로 상기 세포에 투여하는 것으로 이루어진 악성 종양 세포의 분화를 유도하는 방법.
  13. 제12항에 있어서, 악정 종양 세포가 백혈병 세포인 방법.
  14. 제12항에 있어서, 제약학적으로 허용되는 비이클 중에 함유된 화합물을 경구 투여하는 것으로 이루어진 방법.
  15. 제12항에 있어서, 상기 화합물을 비경구투여 하는 것으로 이루어진 방법.
  16. 제12항에 있어서, 상기 화합물을 국소 투여하는 것으로 이루어진 방법.
  17. 제1항의 화합물 1종 이상을 중식성 피부 질환 치료에 효과적인 양으로 포유 동물에 투여하는 것으로 이루어진 포유동물의 중식성 피부 질환의 치료 방법.
  18. 제17항에 있어서, 상기 피부 질환이 건선인 방법.
  19. 제17항에 있어서, 상기 화합물을 경구 투여하는 것으로 이루어진 방법.
  20. 제17항에 있어서, 상기 화합물을 비경구 투여하는 것으로 이루어진 방법.
  21. 제17항에 있어서, 제약학적으로 허용되는 비이클 중에 함유된 화합물을 국소 투여하는 것으로 이루어진 방법.
  22. 1차 및 2차 상피 소체 기능 항진중 환자에겔 제1항의 화합물 1종 이상을 상피 소체의 활성을 억제하기에 충분한 양으로 투여하는 것으로 이루어진 1차 및 2차 상피 소체 기능 항진중 질환을 치료하는 방법.
  23. 제1항의 화합물, 1종 이상 및 제약학적으로 허용되는 부형제로 이루어진 제약 조성물.
  24. 제23항에 있어서, 상기 화합물이 포유 동물에 의해 섭취가능하고 무독성인 액상 또는 고상 비이클 중에 함유된 제약 조성물.
  25. 제12항에 있어서, 상기 화합물이 1α, 25－디히드록시－19－노르－비타민D3인 제약 조성물.
  26. 제23항에 있어서, 상기 화합물이 1α－히드록시－19－노르－비타민D3인 제약 조성물.
  27. 제23항에 있어서, 상기 화합물이 1α, 25－히드록시－19－노르－비타민D2인 제약 조성물.
  28. 제23항에 있어서, 상기 화합물이 1α－히드록시－19－노르－비타민D2인 제약 조성물.
  29. 종양성 질환 환자에게 제1항의 화합물 1종 이상을 종양성 질환의 특성인 악성 종양 세포의 장상세포로의 분화를 유발하는데 충분한 양으로 투여하는 것으로 이루어진 종양성 질환의 치료 방법.
  30. 제29항에 있어서, 상기 화합물이 1α, 25－디히드록시－19－노르－비타민D2인 방법.
  31. 제29항에 있어서, 상기 화합물이 환자에게 무독성이고 섭취 가능한 고상 또는 액상 비이클에 함유된 단일 투여형으로 경구 투여되는 것으로 이루어진 방법.
  32. 제31항에 있어서, 상기 투여형에 활성물질 약 0.5 내지 50㎍이 함유되는 것으로 이루어진 방법.
  33. 제29항에 있어서, 상기 화합물을 1일 약 1 내지 500㎍의 양으로 투여하는 방법.
  34. 제29항에 있어서, 상기 화합물을 국소 투여하는 것으로 이루어진 방법.
  35. 제29항에 있어서, 상기 화합물을 비경구 투여하는 것으로 이루어진 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702408A 1989-03-09 1990-02-16 I9-노르-비타민 d 화합물 KR950013636B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32103089A 1989-03-09 1989-03-09
US321030 1989-03-09
US321,030 1989-03-09
PCT/US1990/000954 WO1990010620A1 (en) 1989-03-09 1990-02-16 19-nor-vitamin d compounds

Publications (2)

Publication Number Publication Date
KR920700200A true KR920700200A (ko) 1992-02-19
KR950013636B1 KR950013636B1 (ko) 1995-11-13

Family

ID=23248877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702408A KR950013636B1 (ko) 1989-03-09 1990-02-16 I9-노르-비타민 d 화합물

Country Status (15)

Country Link
US (7) US5237110A (ko)
JP (1) JPH0667899B2 (ko)
KR (1) KR950013636B1 (ko)
AR (1) AR246254A1 (ko)
AU (1) AU632315B2 (ko)
BR (1) BR9004521A (ko)
CA (1) CA1333616C (ko)
FI (1) FI905489A0 (ko)
HU (2) HU222491B1 (ko)
IL (1) IL93455A (ko)
NO (1) NO904854L (ko)
RO (1) RO109331B1 (ko)
RU (2) RU2055068C1 (ko)
WO (1) WO1990010620A1 (ko)
ZA (1) ZA907119B (ko)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
HU213471B (en) * 1990-09-21 1997-06-30 Bone Care International Process for producing 1alpha-hydroxy-vitamin d4
US6025346A (en) * 1990-09-21 2000-02-15 Bone Care International, Inc. 1α-hydroxy vitamin D4 and novel intermediates and analogues
US5798345A (en) * 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
US5182396A (en) * 1991-03-29 1993-01-26 Nisshin Flour Milling Co., Ltd. 1-hydroxyvitamin d derivatives
ATE143007T1 (de) * 1991-07-05 1996-10-15 Duphar Int Res Vitamin-d derivat, verfahren zu dessen herstellung sowie zwischenprodukte dafür
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
TW267161B (ko) * 1992-11-20 1996-01-01 Hoffmann La Roche
EP0619306B1 (en) * 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
RU2153491C2 (ru) * 1993-07-09 2000-07-27 Лаборатуар Терамекс С.А. Аналоги витамина d, соединения, способы их получения и фармацевтическая композиция
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
PL336231A1 (en) 1997-02-13 2000-06-19 Bone Care International System for aimed therapeutic delivery of vitamin d compounds
US6316642B1 (en) 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5939406A (en) 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US6359152B2 (en) 1997-07-21 2002-03-19 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
EP1064000B1 (en) 1998-03-27 2011-07-06 Oregon Health & Science University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
CA2333256A1 (en) 1998-05-29 1999-12-02 Bone Care International, Inc. Method for making hydroxy-25-ene-vitamin d compounds
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
CA2410880C (en) 2000-05-31 2009-03-03 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
KR100572957B1 (ko) * 2000-07-14 2006-04-24 위스콘신 얼럼나이 리서어치 화운데이션 골 강도를 증가시키기 위한2-메틸렌-19-노르-20(Ｓ)-1α,25-디히드록시비타민 Ｄ3의용도
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
ES2227215T3 (es) 2000-09-08 2005-04-01 Wisconsin Alumni Research Foundation 1 alfa-hidroxi.2.metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.
JP2005504279A (ja) * 2001-09-27 2005-02-10 ザ・コカ−コーラ・カンパニー 食品のビタミン強化
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
WO2003084925A1 (en) 2002-03-29 2003-10-16 Wisconsin Alumni Research Foundation METHOD OF SYNTHESIZING 1α-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
MXPA05009336A (es) * 2003-04-10 2005-11-04 Wisconsin Alumni Res Found Compuestos de 2-propiliden-19-nor-vitamina d.
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
US20050009792A1 (en) * 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
EP1689412A4 (en) * 2003-11-25 2009-03-11 Wisconsin Alumni Res Found VITAMIN D ANALOGUE FOR THE PREVENTION AND TREATMENT OF ADIPOSITAS
WO2005079464A2 (en) * 2004-02-17 2005-09-01 Wisconsin Alumni Research Foundation Vitamin d receptor antagonists and their use in treating asthma
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
AU2005303773A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin D derivatives and anti-proliferative agents for treating bladder cancer
JP2008520691A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−メチレン−１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３およびその使用
NZ563270A (en) 2005-05-10 2010-11-26 Dermipsor Ltd Calcipotriol, polyethylene oxide topical compositions for the treatment of hyperproliferative epidermal diseases
JP2008540513A (ja) 2005-05-10 2008-11-20 ダーミプソル リミテッド スキンケアのための組成物及び方法
CN101223135A (zh) * 2005-07-18 2008-07-16 特瓦制药工业有限公司 帕立骨化醇的制备
JP4882050B2 (ja) 2006-03-15 2012-02-22 日本マイクロバイオファーマ株式会社 インデン誘導体の製造方法およびその製造中間体
US8058265B2 (en) * 2006-04-05 2011-11-15 Wisconsin Alumni Research Foundation 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
KR20090060306A (ko) 2006-08-25 2009-06-11 코우가 바이오테크놀로지, 인크. 비타민 ｄ 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
CA2668544A1 (en) 2006-11-02 2008-05-08 Mercian Corporation Process for production of 1-hydroxy-19-norcyclovitamin d derivative and intermediate for the production
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
US7491712B1 (en) 2007-12-10 2009-02-17 Formosa Laboratories, Inc. Process for preparation of paricalcitol and intermediates thereof
US8026379B2 (en) * 2008-06-20 2011-09-27 Formosa Laboratories, Inc. Paricalcitol intermediates
WO2010009879A2 (en) 2008-07-22 2010-01-28 Azad Pharmaceutical Ingredients Ag Methods for producing paricalcitol
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
EP2393494A1 (en) * 2009-01-27 2011-12-14 Berg Biosystems, LLC Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
ES2607954T3 (es) 2009-07-29 2017-04-04 Kai Pharmaceuticals, Inc. Agentes terapéuticos para reducir los niveles de hormona paratiroidea
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
MX366076B (es) 2009-08-14 2019-06-27 Berg Llc Vitamina d3 y analogos de la misma para tratar alopecia.
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
WO2011119610A2 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
JP6059716B2 (ja) 2011-06-03 2017-01-11 ウイスコンシン アラムニ リサーチ ファンデーション （２２Ｅ）−２−メチレン−２６，２７−シクロ−２２−デヒドロ−１α−ヒドロキシ−１９−ノルビタミンＤ３誘導体
LT2717896T (lt) 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui
MX355063B (es) 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.
AU2014274099A1 (en) 2013-05-29 2015-12-24 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin D
EP3237377A4 (en) * 2014-12-24 2018-08-22 Kyoto University Vitamin d3 derivatives and pharmaceutical use thereof
US20190183908A1 (en) 2016-05-13 2019-06-20 Case Western Reserve University Autophagy activators for treating or preventing skin injury
WO2020049564A1 (en) * 2018-09-06 2020-03-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Pharmaceutical compositions of fumaric acid esters and vitamin d derivatives and use thereof
US11903952B2 (en) 2020-05-27 2024-02-20 Northwestern University Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection
WO2022061193A1 (en) 2020-09-17 2022-03-24 Kyoto University Vdr-silent vitamin d derivative as inhibitors of srebp and pharmaceutical use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410515A (en) * 1981-04-01 1983-10-18 Massachusetts General Hospital Vitamin D glycosides and a method of use
US4448726A (en) * 1983-05-11 1984-05-15 Wisconsin Alumni Research Foundation Ring A- and triene-modified vitamin D compounds
US4769181A (en) * 1983-11-07 1988-09-06 Wisconsin Alumni Research Foundation 1,25-dihydroxyvitamin D2 compounds
WO1985003300A1 (en) * 1984-01-30 1985-08-01 Wisconsin Alumni Research Foundation 1alpha,25-DIHYDROXY-22Z-DEHYDROVITAMIN D COMPOUND
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
CA1314872C (en) * 1986-04-25 1993-03-23 Toshio Nishizawa Fluorine derivatives of vitamin d _and process for producing the same
US5321018A (en) * 1989-03-09 1994-06-14 Wisconsin Alumni Research Foundation Use of 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5185150A (en) * 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
ATE143007T1 (de) * 1991-07-05 1996-10-15 Duphar Int Res Vitamin-d derivat, verfahren zu dessen herstellung sowie zwischenprodukte dafür
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5449668A (en) * 1993-06-04 1995-09-12 Duphar International Research B.V. Vitamin D compounds and method of preparing these compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs

Also Published As

Publication number Publication date
US5587497A (en) 1996-12-24
AU5198890A (en) 1990-10-09
HU215604B (hu) 1999-01-28
WO1990010620A1 (en) 1990-09-20
NO904854D0 (no) 1990-11-08
RU2012558C1 (ru) 1994-05-15
RO109331B1 (ro) 1995-01-30
FI905489A0 (fi) 1990-11-06
AU632315B2 (en) 1992-12-24
US5710294A (en) 1998-01-20
HU222491B1 (hu) 2003-07-28
CA1333616C (en) 1994-12-20
NO904854L (no) 1990-11-08
JPH0667899B2 (ja) 1994-08-31
ZA907119B (en) 1991-10-30
JPH03505330A (ja) 1991-11-21
US5237110A (en) 1993-08-17
US5633241A (en) 1997-05-27
HU9802116D0 (en) 1998-11-30
KR950013636B1 (ko) 1995-11-13
IL93455A0 (en) 1990-11-29
IL93455A (en) 1994-12-29
RU2055068C1 (ru) 1996-02-27
AR246254A1 (es) 1994-07-29
HU902307D0 (en) 1991-07-29
US5618805A (en) 1997-04-08
HUT56538A (en) 1991-09-30
US5561123A (en) 1996-10-01
US5880113A (en) 1999-03-09
BR9004521A (pt) 1992-03-17

Similar Documents

Publication Publication Date Title
KR920700200A (ko) 19-노르-비타민 d 화합물
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
FI863664A (fi) Emulsionskompositioner foer dosering av i vatten svaorloesliga joniserbara hydrofoba laekemedel.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
NZ321738A (en) 3-pyridine-2-heterocyclic substituted imidazoles and medicaments having anti-cancer and cytokine inhibitory activity
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
CA2405796A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
KR900006318A (ko) 피페리디닐 벤즈이미다졸
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
Hay et al. Short course ketoconazole therapy in pityriasis versicolor
KR950703949A (ko) 히드록시카르바졸 화합물의 항산화성 심장보호 용도 및 이를 이용한 치료 방법(Antioxidant Cardioprotective Use of, and Methoed of Treatment Using, Hydroxycarbazole Compounds)
KR950016760A (ko) 치질 치료제
CA2145229A1 (en) Suppressory compositions against hepatic metastases of tumors
KR920004387A (ko) 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
EP0563127B1 (en) Improved treatment method for cancer
KR910018348A (ko) 술포닐아미노치환 비시클로환계 히드록삼산 유도체
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR927002224A (ko) 항종양효과증강제 및 항종양제
OA07589A (fr) Nouveaux dérivés de la nitrosourée et leur préparation.
KR880004810A (ko) 소화성 궤양 치료제
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee
R401 Registration of restoration
EXPY Expiration of term